AAV production with HEK293 cell line and vector technologies

With the AAV market gaining momentum, gene therapy developers are under increasing pressure to advance their AAV-based therapeutics for clinical trials quickly, while managing the risks and the time-consuming steps of gene therapy drug development. Leveraging Lonza expertise and the same tools and technologies implemented for our platform process, you can balance risk and speed, while maintaining high AAV productivity.

Ramp up your AAV production with Lonza’s proprietary HEK293 cell Line and vector technologies

Latest briefing from the Knowledge Center

De-Risk Biologics’ Expression and Manufacturing Through Early In Silico and In Vitro Assessments

Novel engineered plasmids and optimized HEK293 cell line improves AAV productivity

Ramp up your AAV productivity with novel engineered plasmids and optimized HEK293 cell lines

Lonza Shapes Biotherapeutics Development Programs Around Different CMC Paths

Flexibility Is A Critical Aspect Of Biotech-CDMO Relationships

Accessibility Is A Key Difference In Biotech-CDMO Relationships

Communication Is A Foundation For Effective Biotech-CDMO Relationships

Process development for CGT: How soon is too soon? (Geleen)

Why is an integrated service offering so important for the modern pharmaceutical industry?

CMC and CDMO: The Importance of Choosing the Right Partner

How Can You Ensure Successful Late-Phase Development And Launch Of Your Biologic Drug Product?

Erik Lemay, Servier Video Testimonial